Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00085111 · ClinicalTrials.gov registry record · Phase 1
Bevacizumab in Treating Young Patients With Refractory Solid Tumors
A Phase 1 study of Unspecified Childhood Solid Tumor, Protocol Specific, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT00085111: Completed Phase 1 study of Unspecified Childhood Solid Tumor, Protocol Specific, sponsored by National Cancer Institute (NCI).
NCT00085111 is a Phase 1 study of Unspecified Childhood Solid Tumor, Protocol Specific that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 24 participants, below the 1,636-participant average among 13 other Unspecified Childhood Solid Tumor, Protocol Specific trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00085111, a Phase 1 study of Unspecified Childhood Solid Tumor, Protocol Specific, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial is studying the side effects and best dose of bevacizumab in treating young patients with refractory solid tumors. Monoclonal antibodies, such as bevacizumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
Conditions Studied
Interventions
- BIOLOGICAL bevacizumab
Study Locations (1)
California
- COG Phase I Consortium - Arcadia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2003-12 |
| Phase | Phase 1 |
What the finished NCT00085111 record still lists
NCT00085111 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,636-participant average among 13 other Unspecified Childhood Solid Tumor, Protocol Specific trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Unspecified Childhood Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 1 intervention - of which bevacizumab is the first listed.
NCT00085111 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00085111 about?
NCT00085111 is a clinical study titled "Bevacizumab in Treating Young Patients With Refractory Solid Tumors". This phase I trial is studying the side effects and best dose of bevacizumab in treating young patients with refractory solid tumors. Monoclonal antibodies, such as bevacizumab, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
What is the current status of trial NCT00085111?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2003-12.
What conditions does trial NCT00085111 study?
This clinical trial studies the following conditions: Unspecified Childhood Solid Tumor, Protocol Specific.
What interventions are being tested in trial NCT00085111?
The interventions under investigation include: bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00085111?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00085111 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unspecified Childhood Solid Tumor, Protocol Specific
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00085111's enrollment target sits among peer trials
24 12th of 13 higher than 2 of 13 other Unspecified Childhood Solid Tumor, Protocol Specific trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Unspecified Childhood Solid Tumor, Protocol Specific trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease
COMPLETED · Phase 1
-
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
COMPLETED · Phase 1
-
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment
COMPLETED · Phase 1
-
Irinotecan and Cisplatin With or Without Amifostine in Treating Children With Solid Tumors That Have Not Responded to Previous Therapy
COMPLETED · Phase 1
-
Irinotecan in Treating Children With Refractory or Progressive Solid Tumors
COMPLETED · Phase 1
-
Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia